TITLE

Nucleoside-Free Boosted Double PI Regimen: Significant CD4+ T-Cell Recovery in Patients with Poor Immunologic Response Despite Virologic Suppression

AUTHOR(S)
Lehmann, Clara; Jung, Norma; Hofmann, Anika; Cornely, Oliver A.; Wyen, Christoph; Fätkenheuer, Gerd; Hartmann, Pia
PUB. DATE
November 2008
SOURCE
Current HIV Research;Nov2008, Vol. 6 Issue 6, p555
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Antiretroviral therapy in human immunodeficiency virus infection is occasionally associated with poor immunologic responses despite full suppression of viral replication. As some combinations of nucleoside analogues (NA) have been associated with paradoxical depletion of CD4+ T- cells, we postulated that depleting the antiretroviral regimen of NAs would improve quantitative immunological parameters. In a longitudinal prospective study we quantified CD4+ Tcells after removing NAs from antiretroviral therapy. The NA for regimen consisted of atazanavir (300mg qd), saquinavir (1000mg bid), and ritonavir (100mg qd) in 14 patients with immunologic failure despite undetectable plasma HIV-RNA (CD4+ T-cells < 250 cells/µL (<17%) HIV RNA, <= 50 copies/mL). Additionally, we assessed the state of immunologic activation markers (CD38+HLA-DR+ on CD4+ and CD8+ T-cells) by flow cytometry. The regimen was well tolerated. During the 48 week study CD4+ T-cell counts improved significantly (mean and ± SEM [standard error of mean], baseline: 174/µL (12.4%) [15, 5.8%], week 24: 232/µL (14%) [26, 5.3%], week 48: 267/µL (15.4%) [34, 4.3%]) with preservation of full viral suppression (p<0.05). Activation parameters of CD4+ T-cells, but not of CD8+ T-cells, decreased significantly. This treatment strategy may represent an option for patients with poor immunologic responses to antiretroviral therapy despite undetectable viremia.
ACCESSION #
35782012

 

Related Articles

  • Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. Bierman, Wouter F. W.; Scheffer, George L.; Schoonderwoerd, Antoinet; Jansen, Gerrit; Van Agtmael, Michiel A.; Danner, Sven A.; Scheper, Rik J. // Journal of Antimicrobial Chemotherapy (JAC);Aug2010, Vol. 65 Issue 8, p1672 

    Objectives: A possible mechanism for HIV therapy failure is the efflux of HIV drugs from viral target cells or certain body compartments by ATP-binding cassette (ABC) transporters, allowing ongoing viral replication. Here, we investigated the interaction between protease inhibitors (PIs) and ABC...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2000, Vol. 14 Issue 10, p567 

    Presents various medical news briefs related to side effects of antiviral drugs for HIV infections. Ability of protease inhibitors to cause sexual dysfunction; Role of highly active antiretroviral therapy in causing curly hair; Interaction between Viagra and ritonavir or saquinavir.

  • EFAVIRENZ POTENT IN ADULTS.  // AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p170 

    Cites the findings of a DuPont 006 study regarding the use of efavirenz when compared to the protease inhibitor indinavir. Support for the use of efavirenz among HIV patients who are treatment-naive; Random assignments into possible treatment regimens.

  • The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents. Gavegnano, Christina; Kennedy, Edward M.; Baek Kim; Schinazi, Raymond F. // Molecular Biology International;2012, p1 

    Macrophages are ubiquitous and represent a significant viral reservoir for HIV-1. Macrophages are nondividing, terminally differentiated cells, which have a unique cellular microenvironment relative to actively dividing T lymphocytes, all of which can impact HIV-1 infection/replication, design...

  • Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply. Dragin, Loic; Nguyen, Laura Anh; Lahouassa, Hichem; Sourisce, Adèle; Kim, Baek; Ramirez, Bertha Cecilia; Margottin-Goguet, Florence // Retrovirology;2013, Vol. 10 Issue 1, p1 

    Background: Interferon-a (IFN-a) is an essential mediator of the antiviral response, which potently inhibits both early and late phases of HIV replication. The SAMHD1 deoxynucleoside triphosphate (dNTP) hydrolase represents the prototype of a new antiviral strategy we referred to as "nucleotide...

  • Disruption of Type I Interferon Induction by HIV Infection of T Cells. Sanchez, David Jesse; Jr.Miranda, Daniel; Marsden, Matthew D.; Dizon, Thomas Michael A.; Bontemps, Johnny R.; Davila, Sergio J.; Del Mundo, Lara E.; Ha, Thai; Senaati, Ashkon; Zack, Jerome A.; Cheng, Genhong // PLoS ONE;9/16/2015, Vol. 10 Issue 9, p1 

    Our main objective of this study was to determine how Human Immunodeficiency Virus (HIV) avoids induction of the antiviral Type I Interferon (IFN) system. To limit viral infection, the innate immune system produces important antiviral cytokines such as the IFN. IFN set up a critical roadblock to...

  • Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults. Staszewski, Schlomo; Morales-Ramirez, Javier; Tashima, Karen T.; Rachlis, Anita; Skiest, Daniel; Stanford, James; Stryker, Richard; Johnson, Philip; Labriola, Dominic F.; Farina, Dianne; Manion, Douglas J.; Ruiz, Nancy M. // New England Journal of Medicine;12/16/99, Vol. 341 Issue 25, p1865 

    Background: Efavirenz is a nonnucleoside reverse-transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). We compared two regimens containing efavirenz, one with a protease inhibitor and the other with two nucleoside reverse-transcriptase inhibitors, with a standard three-drug...

  • Timing the Emergence of Resistance to Anti-HIV Drugs with Large Genetic Barriers. Arora, Pankhuri; Dixit, Narendra M. // PLoS Computational Biology;Mar2009, Vol. 5 Issue 3, p1 

    New antiretroviral drugs that offer large genetic barriers to resistance, such as the recently approved inhibitors of HIV-1 protease, tipranavir and darunavir, present promising weapons to avert the failure of current therapies for HIV infection. Optimal treatment strategies with the new drugs,...

  • HIV-1 Protease Inihibitors. Eron Jr., Joseph J. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS160 

    Focuses on the role of protease inhibitors (PI) in the antiretroviral therapy for HIV-1 infected patients. Potent activity in vitro of five United States Food and Drug Administration-approved PI agents; Suppression of HIV-1 replication by PI agents with two nucleoside analogue reverse...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics